Cost-effectiveness of screening and treating alcohol use and depression among people living with HIV in Zimbabwe: a mathematical modeling study
Su J, Yeo Y, Jeetoo M, Morojele N, Francis J, Shenoi S, Braithwaite R. Cost-effectiveness of screening and treating alcohol use and depression among people living with HIV in Zimbabwe: a mathematical modeling study. BMC Medicine 2024, 22: 481. PMID: 39428460, PMCID: PMC11492560, DOI: 10.1186/s12916-024-03674-8.Peer-Reviewed Original ResearchConceptsCognitive-behavioral therapyBackgroundAlcohol use disorderTreating alcohol useCompared to baselineLong-acting PrEPDepressive disorderTreat AUDUse disorderMDDMDD screeningAlcohol usePHQ-9Quality-adjusted life yearsAUDCost-effectiveness of screeningSub-Saharan African settingDisordersImpact of screeningIntervention costsHIV infectionHIV transmissionHIV reductionInterventionHIV outcomesHIV epidemicConsiderations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionHigher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia
Ahmad A, Bromberg D, Shrestha R, Salleh N, Bazazi A, Kamarulzaman A, Shenoi S, Altice F. Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia. International Journal Of Drug Policy 2024, 126: 104369. PMID: 38484531, PMCID: PMC11056294, DOI: 10.1016/j.drugpo.2024.104369.Peer-Reviewed Original ResearchMethadone maintenance treatmentNational Institute of Drug AbuseMethadone dosePost-releaseOpioid dependenceMaintenance treatmentMethadone maintenance treatment doseHigher doses of methadoneProspective trialsHighest methadone dosagePost-release outcomesHigher methadone dosesMalaysia’s largest prison.Levels of depressionTreatment of opioid use disorderMonths of releaseDose of methadoneOpioid use disorderLargest prisonHigher dosageIncarcerated peopleIncarceration periodUse disorderMethadone dosageTime-to-event analysis